Nisevokitug
As of the edition of 20 October 2026, Nisevokitug is an antibody: stopped in 2025; acts on TGFB1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Antibody
- Registered trials
- 9, 7 stopped early
- Disease areas
- Cancer; Digestive system; Blood and lymph; Hormones; Lungs and airways; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Nisevokitug.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TGFB1 | Transforming growth factor beta-1 proprotein [Cleaved into: Latency-associated peptide | P01137 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 1 | 0 | 3 |
| Phase 2 | 4 | 0 | 0 | 4 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Novartis | Lead sponsor of trials | 2017 to now |